Abbott is trading at $98.00, 4.3% down in pre-market after announcing plans to separate its Nutrition business into a publicly traded company by the end of 2027. - Reuters reported the pre-market decline followed the announcement and a reduced 2026 sales-growth forecast. - The Nutrition business has approximately $8.5 billion in annual sales. Third-quarter revenue beat estimates; adjusted EPS was $1.42, and full-year EPS guidance was reaffirmed at $5.50–$5.55. - The pre-market price is 4.3% below the October 20 close of $102.45.